Heart Protection Study Trial: A Plain-English Overview of What It Established

At a glance

• Trial name: Heart Protection Study (HPS)
• N: 20,536
• Intervention: Simvastatin 40 mg daily
• Comparator: Matching placebo
• Duration: Mean 5.0 years of treatment; mean 5.3 years of follow-up
• Primary endpoint: First major vascular event (non-fatal MI, coronary death, stroke, or revascularization)
• Key result: 24% relative risk reduction in first major vascular events (p < 0.0001)
• Published: 2002, The Lancet

The Question HPS Set Out to Answer

By the late 1990s, statins had already proven they could prevent heart attacks in men with high cholesterol. The 4S trial (1994) showed simvastatin cut mortality in patients with prior coronary disease. WOSCOPS (1995) showed pravastatin worked for primary prevention in men with elevated LDL.

But major gaps remained. Did statins help women? Patients over 70? People with diabetes but no prior heart attack? Patients whose LDL cholesterol was already below the treatment thresholds used at the time? These were real clinical questions, and no single trial had the statistical power to answer them.

The Heart Protection Study was designed from the ground up to resolve these uncertainties. The investigators enrolled a deliberately broad population, anyone at "high enough vascular risk" to justify randomization, and powered the study to detect benefits in every major subgroup.

Who Was Enrolled

HPS recruited adults aged 40 to 80 from 69 hospitals across the United Kingdom. To qualify, a patient needed a substantial five-year risk of vascular death, defined by at least one of the following:

• Prior coronary heart disease (CHD)
• Prior cerebrovascular disease (stroke or TIA)
• Peripheral arterial disease
• Diabetes mellitus (type 1 or type 2)
• Treated hypertension (for men aged 65 or older)

There was no minimum cholesterol requirement. This was a deliberate design choice. The investigators wanted to test whether baseline LDL mattered, or whether benefit depended only on having enough vascular risk.

The resulting cohort was unusually diverse for a cardiovascular trial of its era. Roughly 25% were women. About 28% were aged 70 or older at enrollment. Nearly 6,000 participants had diabetes. Over 3,400 had cerebrovascular disease without prior coronary events. Around 33% had a baseline LDL below 116 mg/dL (3.0 mmol/L), a level many guidelines at the time would not have flagged for treatment.

What They Were Given

After a six-week run-in on simvastatin 40 mg (to exclude patients who could not tolerate the drug or would not adhere), participants were randomized 1:1:

There was also a 2x2 factorial randomization to antioxidant vitamins (vitamin E 600 mg, vitamin C 250 mg, beta-carotene 20 mg) versus placebo. The vitamin arm showed no benefit and does not affect interpretation of the statin results.

Non-study statin use was permitted if a patient's physician felt it was indicated. By the final year, about 17% of placebo-arm patients were taking a non-study statin, while roughly 18% of simvastatin-arm patients had stopped their allocated drug. This "crossover contamination" diluted the observed treatment effect, meaning the true biological effect of simvastatin was likely larger than the 24% reduction reported.

What Was Measured

The primary endpoint was time to first major vascular event, a composite of:

• Coronary death
• Non-fatal myocardial infarction
• Fatal or non-fatal stroke
• Coronary revascularization (bypass surgery or angioplasty)

Secondary endpoints included all-cause mortality, cause-specific mortality, cancer incidence, and hospitalization. Safety monitoring covered liver enzymes, muscle symptoms, and rhabdomyolysis.

What Was Found

Lipid Changes

Simvastatin 40 mg reduced LDL cholesterol by an average of 1.0 mmol/L (roughly 39 mg/dL) compared to placebo, a relative reduction of about 29%. Total cholesterol fell by approximately 1.2 mmol/L.

Primary Outcome

Over the five-year treatment period, 19.8% of placebo patients experienced a first major vascular event compared with 14.7% of simvastatin patients.

All-cause mortality fell from 14.7% to 12.9%, a 13% relative reduction (p = 0.0003), driven by the drop in vascular deaths.

The Subgroup Results That Changed Practice

This is where HPS distinguished itself from every prior statin trial. The 24% risk reduction held up across subgroups that had never been adequately tested:

The finding in patients with low baseline LDL was arguably the most consequential. It demonstrated that the relative benefit of LDL lowering was independent of the starting point, a principle that the 2018 ACC/AHA cholesterol guidelines later incorporated by shifting away from rigid LDL targets toward risk-based treatment decisions.

Safety

Simvastatin 40 mg showed a clean safety profile across five years:

• Myopathy (CK > 10x ULN with symptoms): 11 cases in the simvastatin group vs. 6 in placebo. No excess rhabdomyolysis cases.
• Liver transaminases (> 4x ULN): No significant difference between groups.
• Cancer: No increase in any cancer type. This was an important reassurance given theoretical concerns about cholesterol-lowering and cancer risk.
• Hemorrhagic stroke: No increase, despite the overall stroke reduction.

The FDA prescribing information for simvastatin continues to reference HPS safety data as part of the risk-benefit evidence.

What the Trial Did Not Show

Honest interpretation requires noting several limitations the investigators themselves acknowledged.

No dose comparison. Every participant received 40 mg. The trial cannot tell us whether 20 mg would have been enough or 80 mg would have been better. Subsequent data, particularly from the SEARCH trial (2010), showed that 80 mg simvastatin increased myopathy risk without proportional benefit, leading the FDA to restrict the 80 mg dose in 2011.

Run-in bias. The six-week run-in excluded patients who stopped the drug early or had side effects. This means HPS enrolled a "tolerator-enriched" population. Real-world discontinuation rates are higher than what the trial observed.

Crossover contamination. As noted, 17% of placebo patients eventually took a statin. The true efficacy of simvastatin 40 mg in a world where the alternative is genuinely no statin is probably larger than 24%.

Limited ethnic diversity. HPS was overwhelmingly a white British cohort. Later trials, including MEGA (Japanese population) and others, confirmed statin benefits across ethnicities, but HPS alone cannot speak to this.

No head-to-head with other statins. Simvastatin 40 mg is a moderate-intensity statin by current classification. Whether high-intensity alternatives like atorvastatin 80 mg would have produced even greater benefit in this population was addressed by subsequent trials like TNT and PROVE-IT.

What HPS Means for Practice Today

HPS did not invent statin therapy. What it did was remove the guardrails. Before HPS, clinicians debated whether to offer statins to women, to older adults, to diabetic patients without heart disease, or to anyone with "normal" cholesterol. After HPS, the answer was consistently yes, if the patient's overall vascular risk was high enough.

Current ACC/AHA guidelines reflect this directly. The four statin-benefit groups, which include diabetic patients aged 40 to 75 and patients with clinical atherosclerotic cardiovascular disease regardless of LDL, trace their evidence base substantially to HPS.

The trial also cemented a conceptual shift. Rather than treating a lab number (LDL cholesterol), clinicians now treat a risk profile. The "lower is better" principle, extended by later trials with ezetimibe and PCSK9 inhibitors, started gaining traction because HPS showed benefit even when LDL was already low.

Simvastatin 40 mg itself has been partially superseded. Atorvastatin and rosuvastatin achieve greater LDL reductions at comparable or lower myopathy risk and dominate current prescribing. But the clinical evidence from HPS remains foundational. The questions it answered, about who benefits from statin therapy, have not needed to be re-asked.

Frequently asked questions

›How large was the Heart Protection Study compared to other statin trials?

HPS enrolled 20,536 participants, making it one of the largest statin RCTs ever conducted. By comparison, the 4S trial enrolled 4,444 patients and WOSCOPS enrolled 6,595. The sheer size of HPS gave it the statistical power to detect benefits in subgroups like women, elderly patients, and diabetics that earlier trials could not adequately assess.

›Did HPS show that simvastatin reduces the risk of stroke?

Yes. Simvastatin 40 mg reduced strokes by 25% compared to placebo (444 vs. 585 events, p < 0.0001). This included both ischemic and hemorrhagic stroke analyzed together, with no increase in hemorrhagic stroke. This was one of the first clear demonstrations that statin therapy prevents strokes in a broad high-risk population.

›Does HPS apply to patients who already have low cholesterol?

Yes. About one-third of participants had baseline LDL below 116 mg/dL (3.0 mmol/L), and the 24% relative risk reduction was consistent in this group. This finding shifted clinical thinking away from treating only elevated LDL and toward treating overall cardiovascular risk.

›Was simvastatin safe over five years in HPS?

HPS found no significant excess of myopathy, liver enzyme elevations, cancer, or hemorrhagic stroke in the simvastatin group. Eleven cases of myopathy occurred in the simvastatin arm versus six on placebo. The trial provided some of the strongest long-term safety evidence for moderate-intensity statin therapy.

›Why don't doctors prescribe simvastatin 40 mg as much today?

While HPS validated simvastatin 40 mg, newer statins like atorvastatin and rosuvastatin achieve greater LDL reductions at comparable safety profiles. The FDA also restricted simvastatin 80 mg in 2011 due to myopathy risk found in the SEARCH trial. For most patients needing moderate- to high-intensity therapy, atorvastatin or rosuvastatin are now preferred.

›Did HPS test simvastatin in patients with diabetes?

Yes. Nearly 6,000 participants had diabetes, including about 3,982 with no prior coronary heart disease. Simvastatin reduced major vascular events by roughly 22% in diabetic patients without prior CHD, providing direct evidence that statins benefit diabetics even before a cardiac event occurs.

›What was the run-in period in HPS and why does it matter?

Before randomization, all participants took simvastatin 40 mg for six weeks. Those who stopped early or had side effects were excluded. This improved adherence rates in the trial but means the safety and tolerability results may look better than what clinicians see in everyday practice, where some patients are less tolerant of statins.

›How did HPS influence current cholesterol treatment guidelines?

HPS was a major driver behind the shift from LDL-target-based treatment to risk-based treatment. The 2013 and 2018 ACC/AHA cholesterol guidelines identify four groups that benefit from statins (including diabetics and patients with clinical ASCVD) regardless of specific LDL thresholds, a framework built substantially on HPS evidence.

›Did the antioxidant vitamin arm of HPS show any benefit?

No. The 2x2 factorial design also tested a combination of vitamin E, vitamin C, and beta-carotene against placebo. The vitamin combination showed no reduction in vascular events, mortality, or cancer. This was one of several large trials that deflated enthusiasm for antioxidant supplementation in cardiovascular prevention.

›How much did crossover between groups affect the HPS results?

By the final year, about 17% of placebo patients were taking a non-study statin and roughly 18% of simvastatin patients had stopped their drug. This diluted the observed treatment difference. The true biological effect of simvastatin 40 mg versus no statin is likely larger than the reported 24% reduction.

References

1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. The Lancet. 2002;360(9326):7-22. PubMed
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344(8934):1383-1389. PubMed
3. SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction. The Lancet. 2010;376(9753):1658-1669. PubMed
4. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
5. FDA. Simvastatin (Zocor) prescribing information. FDA Label